COVID-19 Boosters

Apple Podcasts , SpotifyListen Here

On September 24, 2021, the United States’ CDC made recommendations on who should or may receive a COVID-19 vaccine booster. These recommendations overstepped the vote made by the CDC’s Advisory Committee on Immunization Practices (ACIP), who voted against the recommendation that those 18-64 who have occupational exposure may receive a booster vaccine. In this podcast, we discuss the current evidence as of September 24, 2021 on boosters as well as the evidence-based risk-benefit analysis from the CDC ACIP meeting. Jeremy’s insights can be found at Inside Medicine.

First, the data presented from Pfizer is minimal and involves a total of 312 individuals who received boosters. We have no insight into effectiveness based on this.

In Israel, boosters were available to those ≥60 who completed the series ≥5 months prior beginning at the end of July. Bar-On et al report on this natural experiment.

The data presented at the CDC ACIP meeting can be found in the presentation slides available here.

Pulmonary Embolism Risk Stratification – Right Ventricular Dysfunction

Apple Podcasts , SpotifyListen Here

In this podcast, we review pulmonary embolism (PE) risk stratification and dive into the use of right ventricular dysfunction as a predictor of mortality. We highlight a patient-level meta-analysis by Becattini et al and discuss guidelines on PE risk stratification.

European Society of Cardiology Guidelines (2019)
American College of Emergency Physicians (ACEP) Venous Thromboembolism Guidelines (2018)
Becattini et al
Becattini et al

COVID-19 Vaccines in Pregnancy

updated September 23, 2021

We have several podcasts on the vaccine and specifically in pregnancy. Increasing information on safety has become available, but the basic principles in those podcasts still stand. Podcast on vaccine candidates, podcast on vaccines in pregnancy and lactation, update on vaccines in pregnancy. In May 2021, a large CDC registry of the COVID-19 vaccine in pregnancy was published by Shimabukuro et al. The CDC is tracking pregnant patients who receive the COVID-19 vaccine in 2 ways: (1) the V-safe program (enroll at time of immunization using QR code provided in materials you receive and (2) a pregnancy registry (~5,000 individuals enrolled out of initial V-safe pregnancy population. In the pregnancy registry, the CDC is calling pregnant patients each trimester and post-partum and obtaining records from the obstetric provider. These data have demonstrated no increased risk of pregnancy loss, preterm birth, or congenital anomalies. Of note, many of the pregnancies were not complete at that time, as individuals immunized in the first trimester still had ongoing pregnancies. These data are demonstrated in the graphics below.

The American College of Obstetrics and Gynecology (ACOG) released an updated statement on July 30, 2021 that: recommends that pregnant and lactating individuals be vaccinated against COVID-19. Additionally, the document reinforces that the claims linking COVID-19 vaccines to infertility are unfounded and have no scientific evidence supporting them, recommending vaccination for all eligible people who may consider future pregnancy. Further, although women < 50 years old may receive any COVID-19 vaccine, there is an increased but very rare risk of thrombosis with thrombocytopenia syndrome after the Janssen/Johnson & Johnson vaccine and they may opt for an mRNA vaccine instead (Pfizer or Moderna). The Society for Maternal-Fetal Medicine (SMFM) supports these statements.

A multidisciplinary group at the University of Massachusetts Medical School-Baystate has created decision aids to help pregnant people decide if the COVID-19 vaccine is right for them, which can be found here in 10 languages.

Recurrent, Low-Risk Chest Pain GRACE Guidelines

Apple Podcasts , SpotifyListen Here

The Society for Academic Emergency Medicine has released new Guidelines for Reasonable and Appropriate Care in the Emergency Department (GRACE). These guidelines are aimed at de-implementing low-value care to reduce wasteful medical care. The first guidelines, GRACE-1, target recurrent low-risk chest pain and are published in Academic Emergency Medicine (Musey et al). Previously we covered the American College of Emergency Physician’s clinical policy on non-ST elevation acute coronary syndromes, which does not specifically address recurrent chest pain.

Tranexamic acid in epistaxis

Apple Podcasts , SpotifyListen Here

In this episode we cover the literature on tranexamic acid (TXA) in epistaxis, including a new trial in Annals of Emergency Medicine by Reuben et al, the NoPac trial.

Other references include:

  1. Tibbelin et al. Effect of local tranexamic acid gel in the treatment of epistaxis. ORL J Otorhinolaryngol Relat Spec. 1995 Jul-Aug;57(4):207-9. PMID: 7478455.
  2. Zahed et al.A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. Am J Emerg Med. 2013 Sep;31(9):1389-92. doi: 10.1016/j.ajem.2013.06.043. Epub 2013 Jul 30. PMID: 23911102.
  3. Atabaki et al. A Comparative Study on the Effect of Topical Phenylephrine with Topical Tranexamic Acid in Management of Epistaxis. Nurs Midwifery J. 2017; 15 (7) :488-496
  4. Zahed R, et al. Topical Tranexamic Acid Compared With Anterior Nasal Packing for Treatment of Epistaxis in Patients Taking Antiplatelet Drugs: Randomized Controlled Trial. Acad Emerg Med. 2018 Mar;25(3):261-266. doi: 10.1111/acem.13345. Epub 2017 Dec 9. PMID: 29125679.
  5. Akkan S et al. Evaluating Effectiveness of Nasal Compression With Tranexamic Acid Compared With Simple Nasal Compression and Merocel Packing: A Randomized Controlled Trial. Ann Emerg Med. 2019 Jul;74(1):72-78. doi: 10.1016/j.annemergmed.2019.03.030. Epub 2019 May 9. PMID: 31080025.
  6. Amini et al. Topical Tranexamic Acid versus Phenylephrine-lidocaine for the Treatment of Anterior Epistaxis in Patients Taking Aspirin or Clopidogrel; a Randomized Clinical Trial. Arch Acad Emerg Med. 2020 Nov 19;9(1):e6. PMID: 33313573; PMCID: PMC7720853.
  7. Whitworth et al. Comparative Effectiveness of Topically Administered Tranexamic Acid Versus Topical Oxymetazoline Spray for Achieving Hemostasis in Epistaxis. J Emerg Med. 2020 Feb;58(2):211-216.